Aug. 22 Company Quick Takes: Innovent, Lilly in biologics deal; plus Sobi, Gilead, Themis-Merck, Iconic-Novartis, GW, BeiGene, Clearside, Inex Innovations

Innovent, Lilly in third biologics deal
Innovent Biologics Inc. (HKEX:1801) in-licensed Chinese rights to OXM3 from Eli Lilly and Co. (NYSE:LLY) to treat diabetes. The oxyntomodulin analog -- a dual agonist of GLP-1R and GCGR -- also has the potential to be developed for obesity and non-alcoholic steatohepatitis (NASH). Financial terms were undisclosed. This is Innovent's third collaboration with Lilly; the first two deals largely centered on co-developing biologics from Innovent's pipeline (see "Sourcing Biologics in China").

Sobi sells Priority Review voucher
Swedish Orphan Biovitrum AB (SSE:SOBI) sold a Priority Review voucher to AstraZeneca plc (LSE:AZN; NYSE:AZN) for $95 million. Sobi gained the voucher in its CHF515 million ($519.2 million) acquisition of a company focused on the development of Gamifant emapalumab; the voucher was granted with Gamifant's approval in November for hemophagocytic lymphohistiocytosis (see "Sobi Buying Novimmune Assets as it Refocuses R&D")...